the patient is infected with genotype 3, such as genotype 3a. In another example, the patient is infected with genotype 4, such as genotype 4a. In yet another example, the patient is infected with genotype 5, such as genotype 5a. In still yet another example, the patient is infected with genotype 6, such as genotype 6a.

[0022] In this aspect of the invention, as well as each and every embodiment and example described hereunder, the treatment preferably lasts for less than 24 weeks and does not include administration of interferon to said patient. Such a treatment can, for example, comprise administering Compound 1 or a pharmaceutically acceptable salt thereof, together with an HCV protease inhibitor or an HCV polymerase inhibitor or a combination of an HCV protease inhibitor and an HCV polymerase inhibitor, to said patient. For example, the treatment can comprise administering Compound 1 or a pharmaceutically acceptable salt thereof, together with an HCV protease inhibitor, to said patient. For another example, the treatment can comprise administering Compound 1 or a pharmaceutically acceptable salt thereof, together with an HCV polymerase inhibitor, to said patient. For yet another example, the treatment can comprise administering Compound 1 or a pharmaceutically acceptable salt thereof, together with a combination of an HCV protease inhibitor and an HCV polymerase inhibitor, to said patient.

[0023] In this aspect of the invention, as well as each and every embodiment and example described hereunder, the treatment preferably lasts for no more than 12 weeks (e.g., the treatment lasts for 8, 9, 10, 11, or 12 weeks; preferably, the treatment lasts for 12 weeks), and does not include administration of interferon to said patient. Such a the treatment can, for example, comprise administering Compound 1 or a pharmaceutically acceptable salt thereof, together with an HCV protease inhibitor or an HCV polymerase inhibitor or a combination of an HCV protease inhibitor and an HCV polymerase inhibitor, to said patient. For example, the treatment can comprise administering Compound 1 or a pharmaceutically acceptable salt thereof, together with an HCV protease inhibitor, to said patient. For another example, the treatment can comprise administering Compound 1 or a pharmaceutically acceptable salt thereof, together with an HCV polymerase inhibitor, to said patient. For yet another example, the treatment can comprise administering Compound 1 or a pharmaceutically acceptable salt thereof, together with a combination of an HCV protease inhibitor and an HCV polymerase inhibitor, to said patient.

[0024] In this aspect of the invention, as well as each and every embodiment and example described hereunder, the treatment may or may not include administration of ribavirin to said patient; for example, the treatment includes administration of ribavirin to said patient.

[0025] In another aspect of the invention, there is provided a use of an effective amount of Compound 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treatment for HCV, wherein the medicament is to be administered to an HCV patient, wherein said patient is not genotyped for said treatment.

[0025a] In another aspect of the invention, there is provided a use of an effective amount of Compound 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treatment for HCV, wherein the medicament is to be administered to an HCV patient, wherein said patient is infected with HCV genotype 2, 3, 4, 5, or 6.

[0025b] The present invention also features Compound 1 or a pharmaceutically acceptable salt thereof for use to treat an HCV patient regardless of the specific HCV genotype(s) that the patient has. Such uses are illustrated in the first aspect of the invention described above, including each and every embodiment and example described thereunder.

What is claimed is:

1. ~~A method of treatment for HCV, comprising administering~~ Use of an effective amount of Compound 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treatment for HCV, wherein the medicament is to be administered to an HCV patient, wherein said patient is not genotyped for said treatment.

2. The ~~method~~ use of claim 1, wherein said patient is infected with HCV genotype 2.

3. The ~~method~~ use of claim 1, wherein said patient is infected with HCV genotype 3.

4. The ~~method~~ use of claim 1, wherein said patient is infected with HCV genotype 4.

5. The ~~method~~ use of claim 1, wherein said patient is infected with HCV genotype 5.

6. The ~~method~~ use of claim 1, wherein said patient is infected with HCV genotype 6.

7. The ~~method~~ use according to one of claims 1-6, where said Compound 1 or the salt thereof is to be co-administered with another anti-HCV agent.

8. The ~~method~~ use according to one of claims 1-6, wherein said Compound 1 is to be co-administered with an HCV protease inhibitor or an HCV polymerase inhibitor.

9. The ~~method~~ use according to one of claims 1-6, wherein said Compound 1 is to be co-administered with an HCV protease inhibitor and an HCV polymerase inhibitor.

10. The ~~method~~ use according to one of claims 1-6, wherein said treatment lasts for less than 24 weeks and does not include administration of interferon to said patient.

11. The ~~method~~ use according to one of claims 1-6, wherein said treatment lasts for no more than 12 weeks and does not include administration of interferon to said patient.

12. The ~~method~~ use according to one of claims 1-6, wherein said Compound 1 is to be co-administered with an HCV protease inhibitor or a combination of an HCV protease inhibitor and an HCV polymerase inhibitor, and wherein said treatment lasts for less than 24 weeks and does not include administration of interferon to said patient.

13. The ~~method~~ use according to one of claims 1-6, wherein said Compound 1 is to be co-administered with an HCV protease inhibitor or a combination of an HCV protease inhibitor and an HCV polymerase inhibitor, and wherein said treatment lasts for no more than 12 weeks and does not include administration of interferon to said patient.

14. ~~A method of treatment for HCV, comprising administering~~ Use of an effective amount of Compound 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treatment for HCV, wherein the medicament is to be administered to an HCV patient, wherein said patient is infected with HCV genotype 2, 3, 4, 5, or 6.

15. The ~~method~~ use of claim 13, wherein said patient is infected with HCV genotype 2.

16. The ~~method~~ use of claim 13, wherein said patient is infected with HCV genotype 3.

17. The ~~method~~ use of claim 13, wherein said patient is infected with HCV genotype 4.

18. The ~~method~~ use of claim 13, wherein said patient is infected with HCV genotype 5.

19. The ~~method~~ use of claim 13, wherein said patient is infected with HCV genotype 6.

20. The ~~method~~ use according to one of claims 14-19, wherein said Compound 1 is to be co-administered with an HCV protease inhibitor or a combination of an HCV protease inhibitor and an HCV polymerase inhibitor, and wherein said treatment lasts for less than 24 weeks and does not include administration of interferon to said patient.

21. The ~~method~~ use according to one of claims 14-19, wherein said Compound 1 is to be co-administered with an HCV protease inhibitor or a combination of an HCV protease inhibitor and an HCV polymerase inhibitor, and wherein said treatment lasts for no more than 12 weeks and does not include administration of interferon to said patient.